Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Post ERCP pancreatitis (PEP) occurs in 4 to 5% of patients and is associated with significant
morbidities and occasional mortalities. The use of rectall administered indomethacin and
pancreatic duct stent (PDS) placement have independently been proven to reduce PEP. The
comparative effectiveness of the two methods has however not been studied. It is argued that
in the context of indomethacin, the placement of a PDS is unnecessary. Advocates for PDS
insertion however believe that mechanical decompression of the pancreatic duct is critical in
the prevention of pancreatitis. The investigators propose a multi-centre randomised
controlled trial to compare the use of rectal indomethacin to PDS insertion in high risk
patients in the prevention of PEP.
Phase:
Phase 3
Details
Lead Sponsor:
Chinese University of Hong Kong
Collaborators:
Changhai Hospital Eastern Hepatobiliary Surgery Hospital Tianjin Union Medical Center Xijing Hospital Zhejiang University